New blood treatment may stop bleeding faster in major surgeries
NCT ID NCT05711524
First seen Nov 21, 2025 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tested whether a pathogen-reduced blood product (INTERCEPT fibrinogen complex) can control bleeding better than standard cryoprecipitate in adults undergoing heart or liver transplant surgery. The goal was to see if having this product readily available reduces the need for additional blood transfusions. The study involved 208 participants and compared the total number of blood products used during their hospital stay.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.